We are live on ! Find out more
TRML

Tourmaline Bio

Delisted

TRML was delisted on the 27th of October, 2025.

54 hedge funds and large institutions have $50.6M invested in Tourmaline Bio in 2023 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 18 increasing their positions, 13 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

84% more capital invested

Capital invested by funds: $27.5M → $50.6M (+$23.1M)

38% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 13

13% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 8

2% more funds holding

Funds holding: 5354 (+1)

0.02% more ownership

Funds ownership: 6.43%6.46% (+0.02%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
54
Holders Change
+1
Holders Change %
+1.89%
% of All Funds
0.86%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
9
Increased
18
Reduced
13
Closed
8
Calls
Puts
Net Calls
Net Calls Change

TRML Hedge Fund Activity: Q1 2023 in Review

54 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Tourmaline Bio (TRML) for Q1 2023, worth a combined $50.6M — up 84% from $27.5M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new TRML positions and 8 closed out — a net gain of 1 holder — while 18 added to existing stakes and 13 trimmed.

The largest buyer was BML Capital Management, opening a new position worth an estimated $3.18M. The largest seller was Citadel Advisors, cutting an estimated $4.09M.

  • 54 institutional investors held Tourmaline Bio (TRML) as of Q1 2023, up from 53 in Q4 2022.
  • Funds reported $50.6M of Tourmaline Bio stock for Q1 2023, up 84% quarter-over-quarter.
  • 9 funds opened new Tourmaline Bio positions in Q1 2023 and 8 closed out, a net change of +1 holder.
  • The largest Tourmaline Bio buyer in Q1 2023 was BML Capital Management, an estimated $3.18M added.
  • The largest Tourmaline Bio seller in Q1 2023 was Citadel Advisors, an estimated $4.09M sold.

Based on aggregated 13F filings for Q1 2023.